PT - JOURNAL ARTICLE AU - Skye, Jax AU - Bruss, Joel AU - Toescu, Sebastian AU - Aquilina, Kristian AU - Lola, Gino Bardi AU - Boes, Aaron D. TI - Investigating lesion location in relation to cerebellar mutism following pediatric tumor resection AID - 10.1101/2023.01.12.23284375 DP - 2023 Jan 01 TA - medRxiv PG - 2023.01.12.23284375 4099 - http://medrxiv.org/content/early/2023/01/14/2023.01.12.23284375.short 4100 - http://medrxiv.org/content/early/2023/01/14/2023.01.12.23284375.full AB - Background and Objectives Approximately 25% of pediatric patients who undergo cerebellar tumor resection develop cerebellar mutism syndrome (CMS). Our group recently showed that damage to the cerebellar outflow pathway is associated with increased risk of CMS. Here, we tested whether these findings replicate in an independent cohort.Methods We evaluated the relationship between lesion location and the development of CMS in an observational study of 56 pediatric patients who underwent cerebellar tumor resection. We hypothesized that individuals that developed CMS after surgery (CMS+), relative to those that did not (CMS-) would have lesions that preferentially intersected with: 1) the cerebellar outflow pathway, and 2) a previously generated ‘lesion-symptom map’ of CMS. Analyses were conducted in accordance with pre-registered hypotheses and analytic methods (https://osf.io/r8yjv/).Results We found supporting evidence for both hypotheses. Compared with CMS-patients, CMS+ patients (n=10) had lesions with greater overlap with the cerebellar outflow pathway (Cohen’s d=.73, p=.05), and the CMS lesion-symptom map (Cohen’s d=1.1, p=.004).Discussion These results strengthen the association of lesion location with risk of developing CMS and demonstrate generalizability across cohorts. These findings may help to inform the optimal surgical approach to pediatric cerebellar tumors.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the National Institute of Neurological Disease and Stroke (R01 NS114405-03 & R01 NS114405-01S2) and the Roy J. Carver Trust.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of University of Iowa Carver College of Medicine gave ethical approval for this work. IRB of Great Ormond Street Hosptial gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.CMScerebellar mutism syndromeCMS+individuals with cerebellar mutism syndromeCMSindividuals without cerebellar mutism syndrome